Stay updated with breaking news from Granted Conditional Approval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The application is supported by the Phase 3 CARTITUDE-4 study, which showed significant improvement in primary endpoint of progression-free survival compared to standard regimens CARTITUDE-4 is the... | June 6, 2023
First analysis data from CARTITUDE-4 demonstrated a statistically significant improvement in progression-free survival, with a hazard ratio of 0.26 CARTITUDE-4 is the first randomized study... | June 5, 2023
05.06.2023 - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that results from the Phase 3 CARTITUDE-4 ...
The application to the European Medicines Agency is supported by data from the Phase 3 CARTITUDE-4 study, evaluating the safety and efficacy of cilta-cel in the treatment of patients with relapsed
The application to the European Medicines Agency is supported by data from the Phase 3 CARTITUDE-4 study, evaluating the safety and efficacy of cilta-cel in the treatment of patients with relapsed... | May 25, 2023